$1.61
Today
as of Aug 5, 16:52 ET
Last 30 days
Recent Press Releases & News
Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk
Overview
52-week range
$0.72
$3.65
30% of range
Avg surprise (last 3)
+4.8%
Avg reaction (last 2)
-6.1%
50% positive
Latest IV / EM
301%
EM ±60.2% · $2 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.30 | $-0.32 | +6.2% | +28.6% | -16.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.35 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.33 | $-0.38 | +13.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.42 | $-0.40 | -5.0% | — | +4.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.45 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.37 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.34 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.28 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-53M | — | $-58M | $-54M | $-71M | — | $-77M | $-64M |
| Net income | $-53M | — | $-57M | $-53M | $-68M | — | $-73M | $-59M |
| EPS (diluted) | $-0.30 | — | $-0.35 | $-0.33 | $-0.42 | — | $-0.45 | $-0.37 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $147M | $183M | $129M | $125M | $127M | $142M | $276M | $151M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $153M | $191M | $177M | $223M | $255M | $314M | $349M | $398M |
| Total assets | $154M | $191M | $178M | $224M | $257M | $317M | $353M | $404M |
| Long-term debt | $53M | $55M | $20M | $19M | — | $0 | — | — |
| Total liabilities | $83M | $87M | $46M | $41M | $28M | $30M | $32M | $23M |
| Total equity | $71M | $104M | $132M | $183M | $228M | $287M | $321M | $381M |